shutterstock-194276762-web
bochimsang12 / Shutterstock.com
30 July 2014Big Pharma

AstraZeneca boosts patent portfolio with lung drug acquisition

UK-based pharmaceutical company AstraZeneca has boosted its patent portfolio with the acquisition of rights to Spanish company Almirall’s lung drugs, including Eklira (aclidinium).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
23 March 2026   With Novo Nordisk's core semaglutide patent expired in India last week, the company that built one of the most successful drugs in pharmaceutical history is already fighting on a new front. So what comes next?
Big Pharma
19 March 2026   The Swiss generics giant secures global commercialisation rights as partnership targets multi-billion-dollar loss-of-exclusivity opportunity.
Big Pharma
16 March 2026   Research from the International Trademark Association finds in-house counsel taking on more strategic work while facing shrinking budgets, prompting a shift towards alternative billing and greater use of AI.